Bishal Gyawali, Associate Professor at Queen’s University, shared on X:
“The most practice changing trial from ASCO 2025 is now live on NEJM. If this was a drug, this would be approved today. Globally relevant and low-cost intervention that is not only delaying relapse but actually improving survival.
Perfect case example of a cancer ground shot trial.”
Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head Urologic Oncology at Aura Biosciences, shared Bishal Gyawali’s post, and added:
“So important! Another call to integrate structured physical exercise in cancer care as a standard of care.
Much more than improving QoL
Improving oncological outcomes.”